ARTICLE | Finance
Paid in full
PDL BioPharma, Genentech wrangle over antibody royalties
September 6, 2010 7:00 AM UTC
Paid in full . . .
Two weeks after announcing it got a letter from Genentech Inc. that could put nearly a third of its royalty revenue at risk, PDL BioPharma Inc. (NASDAQ:PDLI) was happy to report last week that Genentech paid its 2Q bill in full. PDL also introduced 3Q10 revenue guidance of $86 million...